Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 10:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Conditions
Prostate Cancer
Interventions
Abiraterone Acetate, Prednisone, LHRHa
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Metastatic Prostate Cancer
Interventions
TAVT-45, Zytiga, Prednisone
Drug
Lead sponsor
Tavanta Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 10 more
Conditions
Prostatic Neoplasms
Interventions
Pembrolizumab, Olaparib, Abiraterone acetate, Prednisone, Enzalutamide, Prednisolone
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
29
States / cities
Fullerton, California • Los Angeles, California • Washington D.C., District of Columbia + 24 more
Conditions
Prostate Cancer
Interventions
Enzalutamide, Abiraterone acetate, Sipuleucel-T
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Prostate Cancer
Interventions
Zytiga® (Abiraterone Acetate), SoluMatrix™ (Abiraterone Acetate)
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
17
States / cities
Laguna Hills, California • Los Angeles, California • San Bernardino, California + 14 more
Conditions
Metastatic Cancer, Neoplasm, Prostate, Castrate-sensitive, Castrate-sensitive Prostate Cancer
Interventions
Abiraterone acetate, Apalutamide, Enzalutamide
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan + 9 more
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Abiraterone acetate, Durvalumab, Methotrexate, Vinblastine, Doxorubicin Hydrochloride, Cisplatin
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Bloomington, Indiana • Houston, Texas
Conditions
Castration-resistant Prostate Cancer
Interventions
BEZ235, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Los Angeles, California • Hackensack, New Jersey
Conditions
Metastatic Prostate Cancer, Prostate Adenocarcinoma
Interventions
Cabozantinib, Atezolizumab, Abiraterone Acetate, Enzalutamide, Prednisone
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older · Male only
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
36
States / cities
Tucson, Arizona • Duarte, California • Fullerton, California + 30 more
Conditions
NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer
Interventions
Afatinib Oral Tablet, Enzalutamide Pill, Abiraterone acetate tablets, MCLA-128
Drug · Biological
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Whittier, California • Lake Mary, Florida • Bethesda, Maryland + 4 more
Conditions
Metastatic Prostate Cancer
Interventions
ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets, Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
Drug
Lead sponsor
ORIC Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
20
States / cities
Colorado Springs, Colorado • Plantation, Florida • Arlington Heights, Illinois + 17 more
Conditions
Prostate Cancer
Interventions
AMG 509, Abiraterone, Enzalutamide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
25
States / cities
Duarte, California • Fullerton, California • San Francisco, California + 22 more